RXRX 8-K 2026-11-02

RECURSION PHARMACEUTICALS, INC. (RXRX) 8-K dated 2026-11-02 — accession 0001601830-26-000144.

RECURSION PHARMACEUTICALS, INC. (RXRX) is a biotechnology company listed on NASDAQ.

RXRX: SECURITIES AND EXCHANGE COMMISSION

This 8-K covers: Results of operations (Item 2.02), Director/officer change (Item 5.02), Reg FD disclosure (Item 7.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported RXRX revenue for 2025-12-31 was $74.7M. Net income was -$644.8M. Revenue was up 26.9% from 2024-12-31 to 2025-12-31. RXRX currently screens at market cap $1.75B.

Not investment advice. The RXRX SEC hub lists recent forms. The stock page is the research view.